Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrate

The New England Journal of Medicine
K SchimpfK Koehler

Abstract

Patients with hemophilia A or von Willebrand's disease who are treated with concentrated preparations of human factor VIII made from unscreened pooled plasma are at substantial risk of contracting human immunodeficiency virus (HIV) infection. The purpose of this study was to investigate whether by treating such patients with a pasteurized factor VIII concentrate that had been heated in aqueous solution at 60 degrees C for 10 hours, HIV infection could be avoided. Eleven hemophilia centers in the Federal Republic of Germany and two in Austria identified 155 eligible patients who had been treated exclusively with pasteurized factor VIII concentrate and had not received any other blood products. Between February 1979 and December 1986 they received a total of 15,916,260 IU of pasteurized factor VIII. The United States was the source of 80 percent of the plasma from which the concentrate was made. By September 1988, these 155 patients had been screened for antibody to HIV type 1 (anti-HIV-1) with a total of 657 tests; all were negative. Sixty-seven patients were also tested once for antibody to HIV type 2 (anti-HIV-2); all these tests were negative as well. It appears that pasteurization effectively inactivates HIV, even in plasma ...Continue Reading

References

Jan 1, 1987·Journal of Virological Methods·L G GürtlerF Deinhardt
Aug 15, 1985·Thrombosis Research·P K Ng, M B Dobkin
Dec 10, 1983·British Medical Journal·M L FletcherC R Rizza

❮ Previous
Next ❯

Citations

Mar 26, 1998·Applied Biochemistry and Biotechnology·K BranovićB Benko
Apr 1, 1992·Baillière's Clinical Haematology·T WeberA F Fleming
Jun 1, 1996·Baillière's Clinical Haematology·P M Mannucci
Aug 1, 1991·Baillière's Clinical Rheumatology·J R York
Jul 13, 2004·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Paul L F Giangrande
Feb 12, 2014·Thrombosis Research·Wolfgang Schramm
Oct 22, 2015·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·UNKNOWN Mitteilungen des Arbeitskreises Blut des Bundesministeriums für Gesundheit
Apr 1, 1991·Baillière's Clinical Haematology·D J King
Feb 1, 1991·Current Problems in Pediatrics·J A Stockman
Oct 3, 2003·Journal of Thrombosis and Haemostasis : JTH·P M Mannucci
Feb 14, 2004·Haemophilia : the Official Journal of the World Federation of Hemophilia·A R ThompsonUNKNOWN Humate-P Study Group
Jan 13, 2000·Haemophilia : the Official Journal of the World Federation of Hemophilia·E SantagostinoA Bianchi Bonomi
Jan 5, 1999·Haemophilia : the Official Journal of the World Federation of Hemophilia·K Hoots, D Canty
Jan 1, 1995·Haemophilia : the Official Journal of the World Federation of Hemophilia·P M Mannucci
Aug 10, 2005·Expert Opinion on Pharmacotherapy·Paul Giangrande
Mar 23, 2002·Paediatric Drugs·Elena SantagostinoPier M Mannucci
Sep 17, 2008·Haemophilia : the Official Journal of the World Federation of Hemophilia·W Schramm
Oct 26, 1989·The New England Journal of Medicine·H R Roberts
May 28, 2020·Haemophilia : the Official Journal of the World Federation of Hemophilia·Pier Mannuccio Mannucci
Jan 1, 1991·Annals of the New York Academy of Sciences·H R Roberts
Sep 17, 2008·Haemophilia : the Official Journal of the World Federation of Hemophilia·G Auerswald, W Kreuz
Nov 18, 2017·Transfusion·Albrecht GrönerNathan J Roth
Mar 10, 2001·Haemophilia : the Official Journal of the World Federation of Hemophilia·W K Hoots
Oct 1, 1990·La Ricerca in Clinica E in Laboratorio·P M MannucciM Cattaneo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.